Selective serotonin re-uptake inhibitors for children and adolescents

被引：0

作者：

Ziervogel C.F. ^{[1
]}

机构：

[1] Department of Psychiatry, University of Cape Town, Rondebosch, 7700, Private Bag

来源：

European Child & Adolescent Psychiatry | 2000年 / 9卷 / Suppl 1期

关键词：

Paediatric psychopharmacology; SSRIs;

D O I：

10.1007/s007870070016

中图分类号：

学科分类号：

摘要：

Objectives: 1) To briefly review the scientific basis for the use of selective serotonin re-uptake inhibitors (SSRIs) in children and adolescents. 2) To review the current data on the efficacy, safety and tolerability in children and adolescents. Method: A Medline search back to 1990 was conducted. Review articles and double blind, placebo controlled trials were critically reviewed. Additional hand searches were performed with key journals and in specific areas of interest for this paper. Results: Most of the published papers are from North America. There is an increasing use of SSRIs in child and adolescent psychiatry. The main disorders studied are mood and anxiety disorders. The data supporting efficacy is still limited. The most robust data is in the treatment of OCD and depression. Conclusion: Taking the limited data together with clinical experience and with adult studies, there is a valuable role for SSRIs as a component of treatment for various child and adolescent psychiatric disorders.

引用

页码：I20 / I26

页数：6

共 29 条

[1]

Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th ed, (1994)

[2]

Ambrosini P.J., Wagner K.D., Biederman J., Glick I., Tan C., Elia J., Hebeler J.R., Rabinovich H., Lock J., Geller D., A multicentre open-label sertraline study in adolescent outpatients with major depression, Journal of the American Academy of Child and Adolescent Psychiatry, 38, pp. 566-572, (1999)

[3]

Beasley C.M., Dornseif B.E., Bosomworth J.C., Sayler M.E., Rampey A.H., Heiligenstein J.H., Thompson V.L., Murphy D.J., Masica D.N., Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression, British Medical Journal, 303, pp. 685-692, (1991)

[4]

Berard R., Ryan N., Adolescent Depression: Efficacy of Paroxetine. 11th Congress of the European College of Neuropsychopharmacology (ECNP), (1998)

[5]

Birmaher B., Waterman G.S., Ryan N., Cully M., Balach L., Ingram J., Bradsky M., Fluoxetine for childhood anxiety, Journal of the American Academy of Child and Adolescent Psychiatry, 33, pp. 993-999, (1994)

[6]

Birmaher B., Yelovich A.K., Renaud J., Pharmacologic treatment for children and adolescents with anxiety disorders, Pediatric Clinics of North America, 45, pp. 1187-1204, (1998)

[7]

Black B., Uhde T., Treatment of elective mutism with fluoxetine: A double-blind, placebo-controlled study, Journal of the American Academy of Child and Adolelscent Psychiatry, 33, pp. 1000-1006, (1994)

[8]

Brent D.A., Holder D., Kolko D., Birmaher B., Baugher M., Roth C., Iyengar S., Johnson B.A., A clinical psychotherapy trial for adolescent depression comparing cognitive, family and support therapy, Archives of General Psychiatry, 54, pp. 877-885, (1997)

[9]

De Vane C.L., Sallee F.R., Serotonin selective re-uptake inhibitors in child and adolescent psychopharmacology: A review of published experience, Journal of Clinical Psychiatry, 57, pp. 55-66, (1996)

[10]

De Veaugh-Geiss J., Moroz G., Biederman J., Cantwell D., Fontaine R., Greist J.H., Reichler R., Katz R., Landau P., Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - A multi-center trial, Journal of the American Academy of Child and Adolelscent Psychiatry, 31, pp. 45-49, (1992)

← 1 2 3 →